PL4223368T3 - Makrocykliczne związki zawierające piperydynę i chinolinę lub chinoksalinę jako inhibitory irak-4 do leczenia stanów zapalnych - Google Patents

Makrocykliczne związki zawierające piperydynę i chinolinę lub chinoksalinę jako inhibitory irak-4 do leczenia stanów zapalnych

Info

Publication number
PL4223368T3
PL4223368T3 PL20956215.6T PL20956215T PL4223368T3 PL 4223368 T3 PL4223368 T3 PL 4223368T3 PL 20956215 T PL20956215 T PL 20956215T PL 4223368 T3 PL4223368 T3 PL 4223368T3
Authority
PL
Poland
Prior art keywords
qunaxoline
irak
quinoline
piperidine
inhibitors
Prior art date
Application number
PL20956215.6T
Other languages
English (en)
Inventor
Takahiko Ito
Misato Takashima
Masakazu Atobe
Koichiro Arai
Tomohisa TOYAMA
Yu Yoshii
Andrew John Potter
Daniel Paul Maddox
Stuart Ray
Nicolas Foloppe
Original Assignee
Asahi Kasei Pharma Corporation
Vernalis (R&D) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corporation, Vernalis (R&D) Limited filed Critical Asahi Kasei Pharma Corporation
Publication of PL4223368T3 publication Critical patent/PL4223368T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
PL20956215.6T 2020-09-30 2020-09-30 Makrocykliczne związki zawierające piperydynę i chinolinę lub chinoksalinę jako inhibitory irak-4 do leczenia stanów zapalnych PL4223368T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2020/037046 WO2022070287A1 (ja) 2020-09-30 2020-09-30 マクロサイクル化合物

Publications (1)

Publication Number Publication Date
PL4223368T3 true PL4223368T3 (pl) 2025-08-11

Family

ID=80951511

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20956215.6T PL4223368T3 (pl) 2020-09-30 2020-09-30 Makrocykliczne związki zawierające piperydynę i chinolinę lub chinoksalinę jako inhibitory irak-4 do leczenia stanów zapalnych

Country Status (11)

Country Link
US (1) US20230357271A1 (pl)
EP (1) EP4223368B1 (pl)
JP (1) JP7422242B2 (pl)
KR (1) KR102871840B1 (pl)
CN (1) CN116348472B (pl)
AU (1) AU2020470423B2 (pl)
CA (1) CA3194090A1 (pl)
ES (1) ES3033780T3 (pl)
MX (1) MX2023003690A (pl)
PL (1) PL4223368T3 (pl)
WO (1) WO2022070287A1 (pl)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2668834T3 (es) 2008-09-08 2018-05-22 Merck Serono Sa Pirimidinas macrociclicas como inhibidores de proteína quinasas
ES2672203T3 (es) 2010-11-19 2018-06-13 Ligand Pharmaceuticals Inc. Aminas heterocíclicas y usos de las mismas
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
WO2014143672A1 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
BR112016006319A2 (pt) 2013-09-27 2017-08-01 Nimbus Iris Inc inibidores de irak e usos dos mesmos
EP3536685B1 (en) 2014-04-04 2022-02-16 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
AU2015292827B2 (en) * 2014-07-21 2019-11-14 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
EP3200787B1 (en) 2014-09-30 2019-09-04 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
NZ732538A (en) * 2015-02-05 2022-04-29 Merck Patent Gmbh Macrocyclic compounds as irak1/4 inhibitors and uses thereof
ES2841452T3 (es) * 2015-02-06 2021-07-08 Merck Patent Gmbh Macrociclos de piridazinona como inhibidores de IRAK y sus usos
EP3267996B1 (en) 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
LT3341367T (lt) * 2015-08-27 2021-04-26 Pfizer Inc. Biciklinis sulietas heteroarilas arba arilo junginiai kaip irak4 moduliatoriai

Also Published As

Publication number Publication date
AU2020470423B2 (en) 2024-01-18
JP7422242B2 (ja) 2024-01-25
US20230357271A1 (en) 2023-11-09
CN116348472B (zh) 2024-12-03
EP4223368A1 (en) 2023-08-09
KR102871840B1 (ko) 2025-10-15
CN116348472A (zh) 2023-06-27
EP4223368A4 (en) 2024-06-19
CA3194090A1 (en) 2022-04-07
EP4223368B1 (en) 2025-05-21
AU2020470423A1 (en) 2023-05-04
JPWO2022070287A1 (pl) 2022-04-07
WO2022070287A1 (ja) 2022-04-07
KR20230092883A (ko) 2023-06-26
MX2023003690A (es) 2023-06-15
ES3033780T3 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
IL288061A (en) Compounds and methods for treating covid-19
PT4065585T (pt) Compostos macrocíclicos substituídos e métodos de tratamento relacionados
IL299704A (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using them
EP3923994A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY
IL241549B (en) inh-1c preparations and methods for preventing and treating disorders associated with esterase inhibitor 1c deficiency
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP4442318A3 (en) Heterocyclic inhibitors of mct4
EP4225923A4 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING COVID-19
EP2536432A4 (en) METHOD FOR TREATING AUTOIMMUNE DEMYELIZING DISEASES AND OTHER AUTOIMMUNE OR INFLAMMATORY DISEASES
IL276817A (en) 7-mutated sulfonimidylfuranone compounds and implications for the treatment and prevention of liver cancer
IL278978A (en) Preparations and methods for treating eczema
EP4263520A4 (en) HETEROCYCLIC PCSK9 INHIBITORS
PL4223368T3 (pl) Makrocykliczne związki zawierające piperydynę i chinolinę lub chinoksalinę jako inhibitory irak-4 do leczenia stanów zapalnych
EP4125835A4 (en) METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING INFLAMMATORY CONDITIONS
LT4214210T (lt) Junginiai ir kompozicijos kaip sppl2a inhibitoriai
GB201913122D0 (en) Compositions and methods for treatment of cholangiocarcinoma
PL3716989T3 (pl) Wyciąg z Helichrysum gymnocephalum do leczenia i profilaktyki dermatoz zapalnych
GB202108485D0 (en) Treatment of inflammatory conditions or diseases
GB202212451D0 (en) Methods and compositions for the treatment of hemangioma
WO2022006377A3 (en) Heterocyclic inhibitors of rho gtpases for the treatment of disease
EP4142664A4 (en) METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
GB201913121D0 (en) Compositions and methods for treatment of cholangiocarcinoma
MX2024008528A (es) Inhibidores heterociclicos de glut9 para el tratamiento de enfermedades.
SMT202000194T1 (it) Composizione comprendente un estere di alfa-tocoferolo per la prevenzione e il trattamento della rinite allergica
HK40109554A (en) Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma